UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. _6_______)*
GEOVAX LABS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
373678200
(CUSIP Number)
Robert T. McNally
President and Chief Executive Office
1900 Lake Park Drive, Suite 380
Smyrna, Georgia 30080
678-384-7220
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 23, 2018
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject of
this Schedule 13D, and is filing this schedule because of
ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box. [ ]
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all
exhibits. See ss.240.13d-7 for other parties to whom copies are to
be sent.
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures
provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 373678200
1.
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF
ABOVE PERSONS (ENTITIES ONLY)
Emory University
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [ ]
(b) [X]
3.
SEC USE ONLY
4.
SOURCE OF FUNDS (see instructions)
OO
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States (State of Georgia)
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7.
SOLE VOTING POWER
4,621,405
8.
SHARED VOTING POWER
Not Applicable
9.
SOLE DISPOSITIVE POWER
4,621,405
10.
SHARED DISPOSITIVE POWER
Not Applicable
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
4,621,405
12.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
(see instructions) [ ]
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.5%
14.
TYPE OF REPORTING PERSON (see instructions)
00
Item 1. Security and Issuer.
Common stock, $0.001 par value, of GeoVax Labs, Inc. (the
"Issuer"). The Issuer's address is 1900 Lake Park Drive, Suite
380 Smyrna, Georgia 30080.
Item 2. Identity and Background.
(a) This statement is filed by Emory University (the
"Reporting Person").
(b) The Reporting Person's business address is
Administration Building 101, 201 Dowman Drive, Atlanta,
Georgia 30322.
(c) The Reporting Person is a private, non-profit
educational institution organized under the laws of the
State of Georgia.
(d) During the last five years, the Reporting Person has
not been convicted in a criminal proceeding.
(e) During the last five years, the Reporting Person has
not been a party to a civil proceeding of a judicial or
administrative body competent jurisdiction and as a result
of such proceeding was or is subject to a judgement, decree
or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect
to such laws.
Item 3. Source or Amount of Funds or Other Consideration.
The Reporting Person was issued a total of 233,905,253 shares
of the Issuer's common stock in connection with a merger that
took place on September 28, 2006 by and between Dauphin
Technology, Inc., GeoVax, Inc. and GeoVax Acquisition Corp. Upon
completion of the merger, Dauphin Technology, Inc. (now GeoVax
Labs, Inc.) issued shares of its common stock, $0.001 par value,
to the shareholders of GeoVax, Inc. in exchange for their issued
and outstanding shares of GeoVax, Inc. common stock. Prior to
the merger, the Reporting Person was a holder of 7,888,320
shares of GeoVax, Inc. common stock (or securities convertible
into GeoVax, Inc. common stock). The securities in GeoVax, Inc.
were issued to the Reporting Person in exchange for the license
of certain technology owned by the Reporting Person and for cash
in the amount of $750,071.28, which were the personal funds of
the Reporting Person.
Item 4. Purpose of Transaction.
The purpose of the September 2006 transaction was to
effectuate the merger between Dauphin Technology, Inc. and
GeoVax, Inc. The acquisition of the shares in 2006 was done
solely in conjunction with the merger. As of the date of this
report, the Reporting Person does not have any plan or proposal:
(i) to acquire additional securities of the Issuer or to
dispose of securities of the Issuer, although it may do either
of these in the future;
(ii) that would result in an extraordinary corporate
transaction, such as a merger, reorganization or liquidation,
involving the Issuer or any of its subsidiaries;
(iii) that would result in the sale or transfer of a material
amount of assets of the Issuer or any of its subsidiaries;
(iv) to change the composition of the Issuer's board of
directors or management, including any plans or proposals to
change the number or term of directors or to fill any existing
vacancies on the board;
(v) that would result in any material change in the present
capitalization or dividend policy of the Issuer;
(vi) that would result in any other material change in the
Issuer's business or corporate structure;
(vii) that would result in any change in the Issuer's charter,
bylaws or instruments corresponding thereto or other actions
which may impede the acquisition of control of the Issuer by any
person;
(viii) that would cause a class of securities of the Issuer to
be delisted from a national securities exchange or to cease to
be authorized to be quoted in an inter-dealer quotation system
of a registered national securities association;
(ix) that would cause a class of equity securities of the
Issuer becoming eligible for termination of registration
pursuant to Section 12(g)(4) of the Act; or
(x) that would result in any action similar to those
enumerated above.
Item 5. Interest in Securities of the Issuer.
On March 23, 2018, the Reporting Person owned 4,621,405
shares, or approximately 3.5%, of the Issuer's common stock.
The Reporting Person's dilution in ownership resulted solely
from a change in the aggregate number of outstanding securities.
The number of outstanding securities as of December 31, 2017 was
obtained from the Issuer's Form 10-K filed on March 23, 2018.
Therefore, based on information available to the Reporting Person, the
Reporting Person ceased to be a beneficial owner as of December
31, 2017, based on information made publicly available on March 23, 2018.
The Reporting Person has the sole power to vote and to dispose
of the shares it beneficially owns; however, the shares owned by
the Reporting Person are restricted as the Reporting Person is
an Affiliate of the Issuer. The Reporting Person did not effect
any transactions in the Issuer's common stock during the past 60
days. No other person has the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the
sale of the Reporting Person's common stock. The name of the
person who has voting or investment control over the securities
owned by the Reporting Person is Christopher Augostini.
Item 6. Contracts, Arrangements, Understandings or
Relationships with Respect to Securities of the Issuer.
Not applicable.
Item 7. Material to Be Filed as Exhibits.
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
COMPANY NAME
By: /s/ Christie D'Amour
Christie D'Amour,
Chief Operating Officer
3/28/2018